Reaction
Ovarian Cancer Recurrent reporting signals
As of the last recalculation, Ovarian Cancer Recurrent appears in 1,580 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is NIRAPARIB (PRR 427.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Niraparib | 495 | 427.4 | 437.2 |
| Olaparib | 355 | 288.0 | 293.0 |
| Rucaparib | 167 | 278.5 | 283.8 |
| Bevacizumab | 245 | 30.7 | 30.7 |
| Paclitaxel (Aibumin-Bound) | 135 | 23.6 | 23.6 |
| Carboplatin | 197 | 23.2 | 23.2 |
| Letrozole Tablets | 79 | 22.7 | 22.8 |
| Paclitaxel | 137 | 19.9 | 19.9 |
| Letrozole | 84 | 18.9 | 18.9 |
| Gemcitabine | 54 | 18.7 | 18.7 |
| Doxorubicin Hydrochloride | 44 | 18.2 | 18.3 |
| Gemcitabine Hydrochloride | 61 | 15.7 | 15.7 |
| Trametinib | 23 | 12.7 | 12.7 |
| Cisplatin | 48 | 8.3 | 8.3 |
| Doxorubicin | 45 | 6.8 | 6.8 |